66 results
8-K
EX-99.1
VTRS
Viatris Inc
9 May 24
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
7:44am
for the mark up for the TSA services provided to Biocon Biologics from the 2023 period.
SG&A and R&D TSA reimbursement: Expenses related to TSA services … is included in other income, net. For comparability purposes, amounts related to the cost reimbursement are reclassified to adjusted SG&A and adjusted R&D
8-K
EX-99.1
VTRS
Viatris Inc
28 Feb 24
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results
7:39am
, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential, Through Global Research and Development Collaboration With Idorsia; Announces R&D Event … the program.
R&D Event
Viatris will hold an R&D Event on March 27, 2024, from 10 a.m. to noon ET, in New York City.
The event will include
8-K
EX-99.1
gqpa29
15 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K
EX-99.1
dgeeav9lp52kpil1w9va
15 Dec 23
Robert J. Coury Remarks at the 2023 Viatris Annual Meeting of Shareholders
4:12pm
8-K
EX-99.1
073d4tbqfn2v7ceo
7 Nov 23
Results of Operations and Financial Condition
4:39pm
PRE 14A
96e povayx
24 Oct 23
Preliminary proxy
4:30pm
8-K
EX-99.2
jppmx3tipo
2 Oct 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
55hisa
2 Oct 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
4q0phq8
7 Aug 23
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Return of Capital to Shareholders
7:38am
8-K
EX-99.1
0vxmiev 1p6l3q2kpxyj
22 May 23
Coury will serve in this new role until the end of 2025
7:46am
8-K
EX-99.1
qrhat4nyzom h6d8
8 May 23
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Return of Capital to Shareholders
7:51am
SC TO-T
EX-99
ti0yqe4t5l2th9 11
1 Dec 22
Third party tender offer statement
6:06am